Opinion|Videos|June 4, 2024
Reflex Testing for Patients with Suspected Lung Cancer
Key opinion leaders highlight findings from a University of Pennsylvania study demonstrating that implementing reflex next-generation sequencing testing can reduce time-to-treatment from 19 days to 10 days, potentially leading to improved overall patient outcomes and survival rates in non-small cell lung cancer.
Advertisement
Episodes in this series
- Please discuss the rationale for conducting liquid-based testing at the time of diagnostic biopsy in patients with suspected advanced NSCLC vs a reflex testing approach. (
Thompson JC, et al. JTO Clin Res Rep, 2022 )- What do prospective data demonstrate?
- Please comment on the goal of having test results available upon the first patient interaction.
- Please discuss data surrounding the impact of concurrent liquid and tissue-based testing on the quality of care in advanced NSCLC. (
Maity, et al. JCO Oncology Practice, 2023 )- What impact does concurrent testing have on time to diagnosis, the need for repeat tissue biopsy, detection of actionable biomarkers?
- What are some limitations associated with tissue-based testing?
- What do data demonstrate regarding the availability of molecular testing results and overall survival of patients with advanced NSCLC? (
Aggarwal, et al. JCO Prec Oncol, 2023 )
Advertisement
Related to this article
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Zipalertinib plus chemotherapy produced a statistically significant, clinically meaningful PFS improvement vs chemotherapy alone at a planned interim analysis.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
4
Adding SBRT to Nivolumab/Ipilimumab Fails to Improve Outcomes in mCRPC
5